New long-term data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) delivered durable efficacy through ...

"Eli Lilly’s Omvoh achieves 91% Crohn’s steroid-free remission at three years" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Crohn’s patients taking Omvoh saw three-years of remission when taking Omvoh, according to new long-term data released by Eli Lilly. 1 The data is the result of the Phase 3 VIVID-2 open label ...

Eli Lilly and Co. LLY on Thursday released promising long-term data regarding its treatment for Crohn’s disease. This news comes as the company reported that more than 90% of patients maintained ...

Eli Lilly said new long-term data showed its Omvoh treatment resulted in durable efficacy for three years in adults with moderately to severely active Crohn's disease.

Eli Lilly operates in the healthcare sector as a global pharmaceutical manufacturer with commercial medicines and a broad research portfolio across immunology, oncology, and metabolic health. Eli ...

Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy and Hold For the Next 3 Years. On February 19, Eli Lilly and Company (NYSE:LLY) released positive results from the Phase 3 VIVID-2 ...

Eli Lilly and Company (NYSE:LLY) edged lower by about 1.5% on Friday, despite Barclays initiating coverage with an overweight rating and a $1,350 price target. The bank highlighted the company's ...

Eli Lilly and Company has reported detailed findings from the ACHIEVE-3 Phase III trial comparing the efficacy and safety of ...

Patients taking a standard dose of CagriSema lost 20.2% of their body weight after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. “The trial did not achieve its primary endpoint of ...

The National Resident Matching Program® (NRMP®) has released the Results and Data Specialties Matching Service®, 2026 Appointment Year report. Size and scale of the Specialties Matching Service (SMS®) ...

TORONTO, ON / ACCESS Newswire / February 19, 2026 / Galway Metals Inc. ("Galway Metals" or the "Company") is pleased to announce that the Company has filed on SEDAR+ a Preliminary Economic Assessment ...